Table 2: Twelve studies selected as sitagliptin as dual therapy group (group 2)
Study |
Design |
Dose |
Follow-up |
N |
Baseline
HbA1c % (SE %) |
Change
of HbA1c % (SE %) |
Charbonnel 2006 [26] |
R, SB1 |
S 100
mg QD4 + M ≥ 1500 mg/day2 |
24wk |
453 |
7.96
(0.81) |
-0.67
(0.051) |
Scott
2008 [27] |
R, DB |
S 100
mg QD + M ≥ 1500 mg/day |
18wk |
91 |
7.75
(0.99) |
-0.73
(0.068) |
Nauck 2007 [28] |
R, DB |
S 100
mg QD + M ≥ 1500 mg/day |
52wk |
382 |
7.48
(0.76) |
-0.67
(0.041) |
Arechavaleta 2011 [29] |
R, DB |
S 100
mg QD + M ≥ 1500 mg/day |
30wk |
443 |
7.48
(0.68) |
-0.47
(0.041) |
Aschner 2012 [14] |
R, O |
S 100
mg QD + M ≥ 1500 mg/day |
24wk |
253 |
8.5
(1.1) |
-1.13
(0.06) |
Pratley
2010 [30] |
R, O |
S 100
mg QD + M ≥ 1500 mg/day |
26wk |
219 |
8.5
(0.7) |
-0.90
(0.066) |
Raz 20083 [31] |
R, DB |
S 100
mg QD + M ≥ 1500 mg/day |
18wk |
95 |
9.3
(0.9) |
-1.00
(0.102) |
Reasner 2011 [32] |
R, DB |
S 50 mg
BID + M 500 mg BID |
18wk |
559 |
9.9
(1.8) |
-2.40
(0.076) |
Scheen 2010 [33] |
R, DB |
S 100
mg QD + M 1500-3000 mg/day |
18wk |
343 |
7.69
(0.9) |
-0.62
(0.038) |
Wainstein 2012 [34] |
R, DB |
S 50 mg
BID + M 500 mg BID |
32wk |
253 |
8.9
(1.3) |
-1.90
(0.076) |
Rigby
2010 [35] |
R, O |
S 100
mg QD + M ≥ 1500 mg/day |
16wk |
55 |
8.17
(0.91) |
-0.40
(0.130) |
Bergenstal 2010 [36] |
R, DB |
S 100
mg QD + M ≥ 1500 mg/day |
26wk |
166 |
8.5
(1.2) |
-0.90
(0.102) |
1SB: single-blinded; O: open-labeled
2S: sitagliptin; M: metformin
3Studies have multiple follow-up visits, and we used the
visit closest to 24 weeks.
4QD: once a day; BID: twice a day